| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | - | 2.637 | 62.033 | 82.489 |
| Total Income - EUR | - | - | - | - | - | - | - | 2.644 | 62.099 | 82.533 |
| Total Expenses - EUR | - | - | - | - | - | - | - | 7.342 | 48.378 | 37.694 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | - | -4.698 | 13.721 | 44.840 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | - | -4.778 | 11.165 | 37.460 |
| Employees | - | - | - | - | - | - | - | 1 | 1 | 1 |
Check the financial reports for the company - Intellivision Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | - | 1.717 | 1.662 | 854 |
| Current Assets | - | - | - | - | - | - | - | 4.596 | 16.219 | 57.135 |
| Inventories | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | - | - | 3.834 | 7.088 | 42.895 |
| Cash | - | - | - | - | - | - | - | 762 | 9.130 | 14.240 |
| Shareholders Funds | - | - | - | - | - | - | - | -4.737 | 6.442 | 37.500 |
| Social Capital | - | - | - | - | - | - | - | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | - | 11.050 | 11.439 | 20.490 |
| Income in Advance | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Intellivision Pharma S.r.l.